WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 9, 2006--PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it is presenting preclinical data on its investigational compound, PPI-2458, at the GTC bio 3rd Cancer Drugs Research and Development Symposium being held in San Francisco, California. The Company's presentation, entitled "Targeted Cancer Therapies: Inhibitors of Methionine Aminopeptidase-2," will be delivered by William Westlin, Ph.D., Vice President, Preclinical Research today at 5:00 p.m. (PST). Dr. Westlin will present preclinical data supporting the Company's rationale for studying its investigational compound PPI-2458 as a targeted molecular therapy for non-Hodgkin's lymphoma and malignant melanoma. A copy of the presentation will be posted on the Company's website at http://www.praecis.com, under "Investors" following the presentation.
